Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 10, 2025 | June 11, 2025 |
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| SCYNEXIS INCSCYX · Entity 7194 | Director | June 26, 2025 | June 30, 2025 |
| Vericel CorpVCEL · Entity 4481 | Director | October 16, 2024 | October 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,830 |
Reported balance
After 2025-06-10 transaction · row 1
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 35,700 · Balance 152,830 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.92 · Expires 2035-06-10 | Direct | 53,600 |
Reported balance
After 2025-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-10 · Grant · Acquired 53,600 · Balance 53,600 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
SCYNEXIS INC
Report date June 26, 2025 · Filed June 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 70,000 |
Reported balance
After 2025-06-26 transaction · row 1
1 source rowRow 1 · 2025-06-26 · Grant · Acquired 23,000 · Balance 70,000 F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2035-06-25 | Direct | 23,000 |
Reported balance
After 2025-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-26 · Grant · Acquired 23,000 · Balance 23,000 F2: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
F2: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
Vericel Corp
Report date October 16, 2024 · Filed October 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,000 |
Ending reported balance
After 2024-10-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-10-16 · Exercise / conversion · Acquired 5,833 · Balance 16,833 Row 2 · 2024-10-16 · Sale · Disposed 5,833 · Balance 11,000 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2024-10-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-10-16 · Exercise / conversion · Acquired 5,833 · Balance 0 F2: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024.
F2: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KERYX BIOPHARMACEUTICALS INC
Report date December 12, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Disposition to issuer · Disposed 27,333 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-12 · Disposition to issuer · Disposed 140,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.
F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 7,796 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2025 Filed Jun 30, 2025 20:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000950170-25-091562 · ownership.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2035-06-25 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091562 · ownership.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 17:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001562180-25-004719 · primarydocument.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2035-06-10 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 17:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004719 · primarydocument.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,830 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-24-043695 · form4.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,833 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,833 | $41.36 | $241,252.88 |
DisclosureSEC source: 0001140361-24-043695 · form4.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 F1 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,833 | $13.05 | $76,120.65 |
DisclosureSEC source: 0001140361-24-043695 · form4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-24-042882 · form4.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 5,833 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,833 | $40.35 | $235,361.55 |
DisclosureSEC source: 0001140361-24-042882 · form4.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 F1 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,833 | $13.05 | $76,120.65 |
DisclosureSEC source: 0001140361-24-042882 · form4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001140361-24-041562 · form4.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 5,834 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,834 | $45.54 | $265,680.36 |
DisclosureSEC source: 0001140361-24-041562 · form4.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 F1 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,834 | $13.05 | $76,133.70 |
DisclosureSEC source: 0001140361-24-041562 · form4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-040228 · form4.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 5,000 shares, became exercisable in three installments, contingent upon continued service to the Company, with the first vesting date on March 20, 2015, which was the date on which the option was granted, and the final vesting date on May 1, 2015. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $48.58 | $242,900.00 |
DisclosureSEC source: 0001140361-24-040228 · form4.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 F1 · shares: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $3.74 | $18,700.00 |
DisclosureSEC source: 0001140361-24-040228 · form4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:08 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-24-076235 · ownership.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-19 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:08 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076235 · ownership.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 16:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001562180-24-004906 · primarydocument.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 16:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004906 · primarydocument.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,130 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024332 · form4.xml · derivative · entry 4 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $47.08 | $0.00 |
DisclosureSEC source: 0001140361-24-024332 · form4.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2034-05-01 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024332 · form4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 3, 2024, or the date of the first Annual Meeting of Stockholders following May 3, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-024332 · form4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 3, 2023. Read SEC document |
| June 15, 2023 Filed Jun 21, 2023 00:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-23-029037 · ownership.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 23, 2023 20:12 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-029622 · ownership.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-23-004954 · primarydocument.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004954 · primarydocument.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,130 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023193 · form4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 3, 2024 or the date of the first Annual Meeting of Stockholders following May 3, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $32.12 | $0.00 |
DisclosureSEC source: 0001140361-23-023193 · form4.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-021499 · form4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-021499 · form4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 27, 2022. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001209191-22-038657 · doc4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038657 · doc4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 16:58 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-22-004975 · primarydocument.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2032-06-08 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 16:58 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004975 · primarydocument.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,130 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 16:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 4,567 | $0.36 | $1,653.25 |
DisclosureSEC source: 0001562180-22-004870 · primarydocument.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,430 F1 · kind: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 2, 2021. Read SEC document |
| May 17, 2022 Filed May 18, 2022 18:04 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOptions (Right to Buy) · Derivative | 42,000 | $3.35 Strike: $3.35 | $140,700.00 |
DisclosureSEC source: 0001209191-22-030206 · doc4.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. Read SEC document |
| April 29, 2022 Filed May 2, 2022 20:07 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 900 | $30.94 | $27,846.00 |
DisclosureSEC source: 0001593968-22-000897 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:12 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000891 · primary_01.xml · derivative · entry 4 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:12 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $31.99 | $0.00 |
DisclosureSEC source: 0001593968-22-000891 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-04-27 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000891 · primary_01.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000891 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-21-002478 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:07 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $39.17 | $195,855.00 |
DisclosureSEC source: 0001593968-21-002478 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $3.74 | $18,700.00 |
DisclosureSEC source: 0001593968-21-002478 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-21-002304 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 20:12 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $50.57 | $252,870.00 |
DisclosureSEC source: 0001593968-21-002304 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $3.74 | $18,700.00 |
DisclosureSEC source: 0001593968-21-002304 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-21-002214 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.